CBFA2T2

CBFA2T2 (MTGR1) is a transcriptional co-repressor of the MTG/ETO family that scaffolds repressive complexes on chromatin to control lineage allocation, stem cell maintenance, and developmental transcription programs (PMID:16227606, PMID:27281218). It was first identified through its strong, NHR2-dependent interaction with the AML1-MTG8 leukemic fusion protein, where it potentiates the fusion's interference with AML1-dependent transcription (PMID:9447981). It assembles classical co-repressor machinery — mSin3A, N-CoR, and HDAC3 — and represses transcription when tethered to DNA (PMID:16227606). CBFA2T2 modulates the activity of multiple sequence-specific transcription factors by direct physical association: it binds the bHLH factors NEUROG2 and TAL1/SCL to repress their target genes (PMID:19646530, PMID:19799863), and it complexes with the Notch effector CSL/RBP-Jκ and with GFI1 to repress HES1 and GFI1 targets in the intestinal epithelium (PMID:25398765). In pluripotent and germline cells it binds the pre-SET/SET domains of PRDM14 and oligomerizes with PRDM14 and OCT4 to stabilize these factors on their genomic targets, an activity required for primordial germ cell maturation and epigenetic reprogramming (PMID:26523391, PMID:27281218). In the intestine MTGR1 acts cell-autonomously to drive secretory lineage maturation, restrain Notch signaling, support epithelial survival and regeneration after injury, and maintain Lgr5+ stem cell function (PMID:16227606, PMID:25398765, PMID:39048708). Its NHR2 domain reads unmodified histone H3K27 to repress metabolic genes spanning glycolysis/gluconeogenesis and the TCA cycle, thereby influencing the α-ketoglutarate/succinate ratio (PMID:41703542). Genetically, loss of MTGR1 in mice confers protection from colitis-associated carcinogenesis through an epithelial-intrinsic mechanism (PMID:21303973).

1. 1998 High

   Established CBFA2T2's first molecular identity — as a dedicated binding partner of the AML1-MTG8 leukemic fusion that enhances its oncogenic transcriptional interference, framing the protein as a co-regulator co-opted in leukemia.

   Evidence Molecular cloning, reciprocal Co-IP, NHR2-region deletion mapping, and G-CSF-dependent proliferation assay in murine myeloid progenitors

   PMID:9447981

   Open questions at the time

   • Did not define the intrinsic repressive machinery recruited by MTGR1
   • No physiological (non-leukemic) function established
2. 2005 High

   Defined the core repressive mechanism (mSin3A/N-CoR/HDAC3 recruitment) and the first in vivo role, placing MTGR1 downstream of progenitor specification to drive intestinal secretory cell maturation.

   Evidence Co-IP with co-repressor components, DNA-tethered repression assays, and Mtgr1-null mouse histological phenotyping

   PMID:16227606

   Open questions at the time

   • Direct DNA-binding transcription factor partners in the intestine not yet identified
   • Did not resolve which secretory program targets are directly bound
3. 2006 High

   Showed the intestinal requirement is epithelial-intrinsic and extends to survival and regeneration after injury, beyond secretory differentiation.

   Evidence Mtgr1-null DSS colitis model with reciprocal bone marrow transplantation and apoptosis/proliferation assays

   PMID:16890610

   Open questions at the time

   • Molecular targets mediating epithelial survival not defined
   • Signaling pathway linkage unresolved at this stage
4. 2008 Low

   Implicated MTGR1 as an intracellular repressor of integrin-dependent neurite outgrowth, hinting at a role in neuronal differentiation control.

   Evidence Genome-wide retroviral GSE screen and siRNA knockdown with neurite outgrowth and GAP-43 readouts in SH-SY5Y cells

   PMID:19026687

   Open questions at the time

   • Single screen plus siRNA phenotype with no direct molecular mechanism established
   • No physical partner or target gene identified
5. 2009 High

   Identified specific bHLH transcription factor partners (NEUROG2 and TAL1/SCL), establishing MTGR1 as a modulator that represses proneural and erythroid transcriptional programs and blocks bHLH/E-protein DNA binding.

   Evidence Co-IP, GST pull-down, domain mapping, reporter assays, ChIP, and in vivo spinal cord neurogenesis analyses; affinity purification/MS in erythroid progenitors

   PMID:19646530 PMID:19799863

   Open questions at the time

   • Whether the same co-repressor machinery is engaged at all bHLH targets not shown
   • Generality across other bHLH factors untested
6. 2011 High

   Demonstrated that MTGR1 is required, cell-autonomously in epithelium, for inflammation-driven colon carcinogenesis, linking its repressive function to tumor promotion.

   Evidence Mtgr1-null AOM/DSS carcinogenesis model with bone marrow transplantation, IHC, and gene expression analysis

   PMID:21303973

   Open questions at the time

   • Direct transcriptional targets driving tumor susceptibility not pinpointed
   • Mechanistic link between repression and apoptosis/inflammation unresolved
7. 2014 High

   Connected MTGR1's intestinal phenotypes to defined signaling effectors, showing it complexes with CSL/RBP-Jκ to repress Notch/HES1 and with GFI1 to control secretory differentiation, with γ-secretase inhibition rescuing the loss phenotype.

   Evidence Co-IP, HES1 reporter assays, Mtgr1-null mouse GSI rescue, laser-capture crypt transcriptomics, and enteroid culture

   PMID:25398765

   Open questions at the time

   • Whether MTGR1 represses CSL directly at chromatin via genome-wide occupancy not mapped
   • Relative contribution of Notch vs GFI1 arms not dissected
8. 2015 High

   Provided structural and genomic resolution of a key partnership, showing CBFA2T2 binds the PRDM14 pre-SET/SET domains and co-occupies its targets to support pluripotency gene expression and PGC formation.

   Evidence Crystal structure of the PRDM14–MTGR1 complex (monobody-assisted), Co-IP, ChIP-seq co-occupancy, structure-guided mutants/monobody, and mESC/PGC assays

   PMID:26523391

   Open questions at the time

   • Did not establish the higher-order scaffold composition beyond the binary interface
   • In vivo germline requirement addressed in vitro only
9. 2016 High

   Established the oligomeric scaffold model in vivo, showing CBFA2T2 self-associates to stabilize PRDM14 and OCT4 on chromatin and is essential for primordial germ cell maturation and epigenetic reprogramming.

   Evidence Co-IP of CBFA2T2–PRDM14 and CBFA2T2–OCT4 complexes, oligomerization assays, chromatin stabilization assays, and Cbfa2t2-null mouse PGC phenotyping

   PMID:27281218

   Open questions at the time

   • Stoichiometry and structural basis of the chromatin-stabilizing oligomer not resolved
   • How scaffold activity intersects with co-repressor recruitment unclear
10. 2018 Medium

    Extended CBFA2T2 function to mesenchymal lineage commitment, positioning it as a positive regulator of osteogenesis that restrains EHMT1-mediated H3K9me2 deposition at the RUNX2 promoter.

    Evidence siRNA knockdown, ALP/Alizarin Red assays, marker expression, and ChIP for H3K9me2 at the Runx2 promoter

    PMID:29378183

    Open questions at the time

    • Direct vs indirect control of EHMT1 not established
    • Physical interaction with EHMT1 or RUNX2 not demonstrated
11. 2020 Medium

    Showed an analogous, lineage-specific role in adipogenesis, where CBFA2T2 limits repressive H3K9 methylation at the CEBPA promoter to enable adipogenic differentiation.

    Evidence siRNA knockdown, Oil Red O staining, marker analysis, and ChIP for H3K9me2/me3 at the CEBPA promoter

    PMID:32703401

    Open questions at the time

    • Mechanism linking CBFA2T2 loss to increased H3K9 methylation not defined
    • No direct chromatin occupancy data for CBFA2T2 at CEBPA
12. 2024 Medium

    Refined the intestinal role to stem cell biology, showing MTGR1 maintains Lgr5+ ISC function cell-intrinsically — its loss expands but deregulates ISCs and renders organoids unable to survive ex vivo.

    Evidence Mtgr1-null crypt analysis, flow cytometry for Lgr5+ cells, single-cell/bulk transcriptomics, and ex vivo organoid culture

    PMID:39048708

    Open questions at the time

    • Direct ISC transcriptional targets not identified
    • How stem cell maintenance integrates with the Notch/GFI1 axes unresolved
13. 2026 Medium

    Identified a chromatin-reading activity, showing the NHR2 domain recognizes unmodified H3K27 to repress carbon/energy metabolism genes and shape the α-ketoglutarate/succinate ratio and H3K27me3 landscape.

    Evidence Biochemical histone-binding assays, NHR2 domain mapping, metabolic transcriptome analysis, metabolite quantification, and H3K27me3 measurement

    PMID:41703542

    Open questions at the time

    • Structural basis of unmodified-H3K27 recognition by NHR2 not solved
    • Causality between metabolite shifts and H3K27me3 demethylase activity not directly demonstrated

• How CBFA2T2's distinct activities — NHR2-mediated oligomerization, co-repressor recruitment, partner-specific transcription factor binding, and H3K27 reading — are integrated and selected in different cell types remains unresolved.
• No unified model of how scaffold vs reader vs co-repressor modes are deployed contextually
• Genome-wide direct target maps across tissues lacking
• Structural basis of NHR2 multifunctionality not fully defined